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According to Jerry’s commentary [1], exogenous oestrogen
and progesterone potently inhibit tumorigenesis, representing
an interesting strategy to prevent breast cancer, but we feel
that the concerns noted by Jerry deserve further comment.
According to the Million Women Study [2], when proges-
terone was included in the hormone replacement therapy
(HRT) formulation, the odds ratio fell from 1.3 to 1.1,
indicating a protective effect exerted by progesterone, though
no significant difference in the relative risk of ovarian cancer
was registered in the subgroups of women who used
oestrogen only compared with those who used the combina-
tion. Long durations of use of unopposed oestrogen and of
oestrogen plus progestin, especially sequential regimens,
have been reported to be associated with increased ovarian
cancer risk. In preclinical models, combined progestins
circumvent the anti-apoptotic action of the long isoform of
Fas-associating protein with death domain-like interleukin-1
beta-converting enzyme (FLICE)-like inhibitory protein, an
anti-apoptosis mediator, representing an effective therapy for
ovarian cancer cells [3]. In premenopausal women, combined
oral contraceptives (OC) have been described to be effective
at decreasing the risk of epithelial ovarian carcinoma, even
though the strongest risk reduction has been associated
either with low- or high-potency progestin formulations.
Some synthetic progestins, when added to oestrogen in HRT
for menopausal symptoms, have been reported to increase
the risk of breast cancer more than oestrogen alone.
Progestin use in breast cancer survivors is associated with an
increased breast cancer risk compared with its non-use [4].
However, outside pregnancy, progesterone endogenously
produced or exogenously administered does not have a
cancer-promoting effect on breast tissue. The greater breast
cancer risk related to the use of HRT containing oestrogen
and synthetic androgenic progestin (19-nortestosterone
derivatives) could be due to the non-progesterone-like effects
enhancing the oestrogen proliferative effect on oestrogen-
sensitive cancer cells.
In postmenopausal women, progesterone is added to prevent
the carcinogenic effect of oestrogen on the uterus [5]. In
premenopausal women, the potency of the progestin in most
OC appears adequate to provide a protective effect against
endometrial cancer. Higher progestin-potency OC may be
more protective than lower progestin potency OC among
women with a larger body habitus. Progestagens counteract
the adverse effect of oestrogens on the endometrium, the
effect being greater the more days every month that they are
added to oestrogen and the more obese that women are.
Finally, because hormones may play a crucial role in the
development of breast, endometrial and ovarian cancer, the
impact on cancer risk of progestins included in HRT or OC
formulations remains a major interest.
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FLICE = Fas-associating protein with death domain-like interleukin-1 beta-converting enzyme; HRT = hormone replacement therapy; OC = oral
contraceptive.